Johnson and Johnson files EU notification and extends DePuy offer:
This article was originally published in Clinica
Johnson & Johnson has filed the required notification relating to its proposed $3.5 billion takeover of orthopaedics company DePuy with the European Commission. At the same time, it has extended its tender offer for the Roche subsidiary to October 16. The Commission has a month to complete its preliminary examination and determine whether it needs to investigate the proposed deal further. As clearance under EU merger control regulations would not be obtained before the scheduled expiry date for the offer of October 5, J&J and DePuy agreed to the extend the offer. If the deal goes through, J&J would also gain ownership of the spinal implant company, AcroMed, which DePuy recently acquired.
You may also be interested in...
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.